 |
인쇄하기
취소
|
Bayer HealthCare’s Xarelto approved in Korea
Bayer HealthCare’s Xarelto approved in Korea
The Korea Food and Drug Administration granted on April 13 Bayer HealthCare marketing authorization for the anticoagulant Xarelto (rivaroxaban), taken as one tablet, once-daily, for the prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip or total knee replacement surgery.
Bayer will start marketin...
The Korea Food and Drug Administration granted on April 13 Bayer HealthCare marketing authorization for the anticoagulant Xarelto (rivaroxaban), taken as one tablet, once-daily, for the prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip or total knee replacement surgery.
Bayer will start marketin...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.